Cell-based therapies in the retina have been associated with the recovery of visual function in animal models of retinal degeneration. This review covers the current status of such therapies with regard to the source of the donor cells, their integration, and their impact on the degenerating host retina. Emphasis is also put on the importance of a careful interpretation of what is meant by ''recovery of visual function''. Two main approaches are considered here: (1) the use of human embryonic stem cell derived retinal pigment epithelial (RPE) cells to rescue photoreceptors in an animal model of RPE defect; and (2) the use of photoreceptor precursors to repair the degenerating neural retina. The current conclusions are that major hurdles have to be dealt with, such as finding an appropriate and ethically compliant donor cell source that would yield protracted survival and integration of the replacement retinal cells, and that there is no evidence yet that cell-based therapies can allow the long-term preservation or recovery of conscious vision.
What is vision?
Vision is a complex sensory process permitting eye-bearing organisms to detect the features of any object in their environment such as size, color, orientation, motion, and distance. The first steps in vision take place in the retina, a thin sheet of neural tissue (approximately 400 lm thickness in humans, and 200 lm in rodents) lining the posterior pole of the eye. Optical images formed on the retina are transformed into neural images according to three sequential stages: (1) transduction of the light signals into electrical changes by the photoreceptors in the outer retina; (2) synaptic transmission of these electrical changes to cells in the inner retina; and (3) further synaptic transmission to retinal ganglion cells, the axons of which collect in the optic nerve, providing the only output to the brain.
Normal vision requires a healthy eye and retina, i.e. adequate transparency of the optical media, proper lens focusing upon the retinal plane, intact retinal organization and an efficient blood vessel network. Damage to any of these structures can lead to visual impairment with blindness as the end result.
Loss of vision: Etiology
Vision loss affects approximately 3.4 million US citizens over the age of 40; and this number is expected to increase twofold in the next three decades. The leading causes of blindness in the US are cataract (17.2%) and various forms of retinal degeneration, namely aged-related macular degeneration (AMD; 7.6%), diabetic retinopathy (DR; 3.4%), glaucoma (1.9%) and retinitis pigmentosa (RP; 0.34%) (online data available from National Eye Institute website: http://www.nei.nih.gov/eyedata/pbd_tables.asp). marily the rods. The etiology is usually attributed to primary defects located either in the RPE cells (playing an essential role for photoreceptor function and survival) or the photoreceptors themselves.
Therapeutic approaches designed to rescue or repair the degenerating retina
Over the last 25 years, several therapeutic approaches have been designed to delay the pathological processes leading to blindness. Some of them are summarized in Table 1 . While a few of these treatments are currently used in the clinic (essentially surgical approaches, with limited success), most are still in their infancy or at best at the pre-clinical trial (phase 1) level.
Recently, two experimental approaches received considerable media coverage emphasizing the promise of relying on cell-based therapies to rescue degenerating retinas in humans. The first approach consisted of using RPE cells derived from multiple human embryonic stem cell lines as a mean to improve photoreceptor survival in an animal model of RPE defect, the Royal College of Surgeons (RCS) rat . The second approach consisted of studying the ability of neonatal photoreceptor precursors to differentiate and integrate into the outer nuclear layer (ONL) in both the intact and the degenerating retina of mature mice (MacLaren et al., 2006) .
Taking these findings into consideration, this review addresses the potential and limitations of current experimental cell-based therapies for blindness, while keeping in mind that in order to be successful, cell therapy should fulfill four fundamental criteria. The desired cells should: (1) multiply in sufficient quantities, (2) organize into functional units, (3) survive and integrate into the host, and ultimately, (4) lead to the preservation of vision without causing deleterious side effects.
Using human embryonic stem cell-derived RPE cells to rescue photoreceptors in the RCS rat
The RCS rat is a widely used model of retinal degeneration in which a mutation of the receptor tyrosine kinase mertk gene (D'Cruz et al., 2000) precludes RPE cells from phagocytosing outer segment debris, leading ultimately to the death of healthy photoreceptors within a three-month period. Morphological changes in photoreceptor outer segments appear as early as P16 (when the eyes open), and by P120 only scattered photoreceptor cells (cones) remain. Mutations in the human mertk gene cause a rare form of RP: a total of four patients has been reported in the literature (Gal et al., 2000; McHenry et al., 2004) .
Ideally, the ultimate cell-based therapy, aimed at preserving photoreceptor function in this model, would be the replacement of the defective cells by RPE cells resuming a normal function in the host (for a review see Lund et al., 2001) . There is recent evidence that many ethically acceptable sources of multipotent human stem cells can reliably be induced to differentiate into cells having numerous RPE-specific genes and phagocytic function in vitro (Klimanskaya et al., 2004) . Moreover, RPE cells derived from human embryonic stem cells have been reported to ''rescue visual function'' when injected into the subretinal space of RCS rats at an age when photoreceptor cell death begins ; we will address the meaning of ''visual function'' later. In parallel with the need to develop further embryonic stem cell-related strategies to treat RPE-based retinal degeneration, crucial issues must be elucidated prior to considering clinical trials.
Limited integration of the donor cells in the host
Despite their ability to form a monolayer with cobblestone morphology in vitro (Klimanskaya et al., 2004) , grafted human embryonic stem cell-derived RPE cells remain aggregated in the subretinal space at the injection site, and are incapable of forming a monolayer over the defective RPE. This failure has three direct consequences: first, photoreceptor rescue covers a limited area of the retina (optimal in the graft sector but comparable to dystrophic levels in remote areas, 1 mm away from the graft border); second, the host retina is locally pushed toward the lens, implying a strong defocussing (hypermetropialike) and distortion of the retinal images in the rescued area; and third, the persistence of cell aggregates might cause deleterious effects analogous to the ones seen after retinal detachments, such as causing photoreceptor death and extensive retina remodeling (for a review see Fisher, Lewis, Linberg, & Verardo, 2005) . In theory, a series of concomitant injections would be needed in order to rescue photoreceptors over the whole retina. Such a strategy, however, would unavoidably produce large-scale anatomical deformations of the retina (''waffled retina'') and associated compound distortions of the visual image (metamorphopsia) in addition to the ultimate risk of retinal detachments. The above-mentioned side effects are readily observed with human Schwann (hSC) cells, but seem absent with human RPE (hRPE) cell lines including ARPE-19 (Lund et al., 2001) . While the former remain aggregated into several clumps, the latter progressively forms a monolayer, covering significant retinal area by 15 weeks after injection (Wang, Lu, Wood, & Lund, 2005) . Of note, the hRPEderived cell lines studied so far display structural properties (cell polarization, intercellular tight junctions and barrier function) characteristic of native RPE cells (Dunn, Aotaki-Keen, Putkey, & Hjelmeland, 1996; Kanuga et al., 2002) . Potentially, in situ layering could be cell-type specific, while independent of xenograft conditions. Further studies are therefore required to examine whether human embryonic stem cell-derived RPE cells have morphological specializations of RPE cells and redistribute over the retina at increasing post-grafting time points.
However, understanding the reasons why both cell lines fail to rapidly expand into the subretinal space might be even more critical as a step toward achieving successful cell-based therapies. The specific factors to consider include the influence of: (1) tropic factors in guiding the expansion of donor cells, (2) the interaction between extracellular matrix proteins and their respective integrin receptors, (3) toxic debris produced by shed outer segments and dying donor cells, (4) the defective host RPE on the growth and division of the donor cells (RPE cells contain high levels of retinoids, which are known to be able of inhibiting cellular division; Campochiaro, Hacket, & Conway, 1991) , (5) mechanical constraints due to the close apposition of the photoreceptor outer segments with the RPE cells, and (6) both host and donor cell motility. Of note, some of these above-mentioned influences might be bypassed by surgical techniques designed to allow the deposition of already formed cellular monolayers along the host subretinal space (Seiler & Aramant, 2005) . Moreover, although limited by the host photoreceptors themselves (Zhang, Arner, Ehinger, & Perez, 2003) , the integration of such monolayers into the host may be improved by concomitant pharmacological modulations of the extracellular matrix (Suzuki, Mandai, Akimoto, Yoshimura, & Takahashi, 2006) .
Mode of action of the donor cells: a paracrine effect
Photoreceptor rescue ultimately requires the phagocytosis of outer segment shed debris and the release of trophic factors by the donor cells. While freshly harvested allogeneic RPE cells can resume in vivo the phagocytic function (Lavail, Li, Turner, & Yasumura, 1992) , it is unclear whether this is also true for the embryonic stem cell-derived RPE cells in vivo. For a clear confirmation that resumed phagocytosis does contribute to the reported rescue in RPE transplantation studies, subretinal injection of an RPE cell line having the mertk mutation must be undertaken in the RCS rat. Without this crucial experiment, the current evidence supports a paracrine survival effect: (1) hRPE cell lines used for transplantation express and release trophic factors that are essential for photoreceptor survival (Kanuga et al., 2002) ; (2) anatomical observations of retinas as well as visual response recordings from the CNS both indicate that the area of rescue largely exceeds the retina areas with persisting donor cells; (3) subretinal transplantation of cells incapable of phagocytosis, including hSC cells, umbilical tissue-derived cells, placenta-derived cells, and to a lesser degree, bone marrow-derived mesenchymal stem cells, yields very similar results as with RPE transplantation (Lawrence et al., 2004; Lund et al., 2007; Wang et al., 2005; and (4) photoreceptor rescue has been observed with human fetal fibroblasts engineered to produce CNTF (Huang et al., 2006) as well as with human cortical progenitors that release IGF-1 and FGF-2 (Gamm et al., 2007) . A paracrine action might also underlie the results reported by Lund et al. (2006) , since the anatomical rescue widely exceeds the area containing the transplanted human embryonic stem cell-derived RPE cells. These cells express, among other trophic factors, the PEDF gene and protein (Klimanskaya et al., 2004) , a trophic factor known to have protective and morphogenetic effects on photoreceptors (Aymerich, Alberdi, Martinez, & Becerra, 2001; Barnstable & Tombran-Tink, 2004; Cayouette, Smith, Becerra, & Gravel, 1999; Imai, Yoneya, Gehlbach, Wei, & Mori, 2005) . Therefore there is yet no clear evidence that the observed retinal rescue by grafted human embryonic stem cell-derived RPE cells is mediated via their ability to correct the primary phagocytic defect that occurs in RCS rats.
In fact, the paracrine delivery of trophic factors in cellbased therapies appears to have a generalized rescue effect that is independent of the primary genetic defect. For instance, transplantation of rods in rodless mice can halt the secondary death of cones via the delivery of a rodderived cone viability factor (Mohand-Said, Hicks, Dreyfus, & Sahel, 2000; Leveillard et al., 2004) . A further example comes from dogs deficient for PDE6-beta and S334-ter rats in which photoreceptors could be rescued with the ocular transplantation of a human retinal cell line engineered to produce CNTF (Tao et al., 2002) . Lastly, Keegan et al. (2003) showed that photoreceptors could be rescued in rho À/À mice by injecting in their subretinal space Schwann cells, which were shown to produce several factors such as CNTF and BDNF.
While the paracrine delivery of survival factors by grafted cells appears sufficient to rescue photoreceptors, this effect rapidly fades away in all models studied. At 6 weeks post-injection, electroretinogram responses (which reflect the summation of activity from the whole retina) recorded from RCS retinas having received human embryonic stem cell-derived RPE cells are significantly larger than in sham-injected retinas, but undergo severe impair-ments 4 weeks later, as previously reported for other RPE cell lines (Sauvé, Pinilla, & Lund, 2006) . Such functional deteriorations over time are also evidenced by other tests involving CNS visual responsiveness and visually guided behaviors (Girman, Wang, & Lund, 2005; McGill et al., 2004) . These declines can be attributed in part to the massive death of the donor cells. Less than 2% of the initially delivered ARPE-19 cells persist in the host subretinal space at 15 weeks post-injection, some (0.2%) being still present at 7 months post-injection . Nevertheless, by this age, the persistence of a few ARPE-19 cells is associated with the rescue of some photoreceptors only over very small retinal areas while virtually no photoreceptors are detected in age-matched dystrophic rats. Furthermore, these areas are associated with the visual responsiveness of individual neurons in the primary visual cortex (Girman, Wang, & Lund, 2003) . Whether such circumscribed retinal areas of rescue alone are responsible for the limited preservation of visual acuity as evaluated with tests such as head tracking (Coffey et al., 2002) and visual ''y'' water maze (McGill et al., 2004 ) is unknown. Finally, whether human embryonic stem cell-derived RPE cells lead to better rescue than the RPE cell line ARPE-19 isolated from an adult human is also unknown.
Manipulating stem cells or improving surgery?
The main rationale given for using human embryonic stem cell lines over adult-derived RPE cell lines is the ability to produce differentiated RPE cells in vitro, while opening the possibility of manipulating the cells to render them less immunogenic. Other advantages include the ability to maintain pathogen-free non-differentiated cells in culture with the flexibility of expanding large quantities on demand. In this regard, the key issues are the following: (1) whether the donor cells must possess an RPE phenotype to produce the reported rescue effects and (2) whether human embryonic stem cells are the optimal cell source. The transplantation of mature cells, which are not RPE in phenotype, such as syngeneic Schwann cells McGill et al., 2007) can yield similar beneficial outcomes as obtained with human embryonic stem cellderived sources. Moreover, since the therapeutic efficacy of donor cells appears to rely on a paracrine effect, then, the essential aims would be the production of trophic factors by the transplanted cells. Indeed, in addition to adult syngeneic Schwann cells, numerous cell sources, that are non-immunogenic and easily available, have been successfully used to rescue retina function in RPE-based retina degenerations. The possibility remains to manipulate these other cell types to produce trophic factors and to minimize rejection. As such, the transfection of autologous sources would be optimal. However, since paracrine-based rescue have short lasting effects, multiple cell injections would be required. Such an endeavor would be laborious, costly, and unfeasibly scaled up. Furthermore, even assuming that a constant level of trophic factors can be maintained, there is no evidence that this alone would preserve photoreceptors indefinitely if the primary defect itself is not corrected.
An additional complication that must be considered when doing subretinal cell injections is the formation of a donor cell layer on the dysfunctional host RPE cells. A potential strategy could involve a debridement of the defective RPE layer. It has been shown that bone marrowderived cells are able to home and regenerate the host RPE after acute injuries (Harris et al., 2006) ; and that a de novo RPE growth occurs after local debridement (Del Priore et al., 1993; Valentino et al., 1995) . However, this procedure presents disadvantages: (1) it induces an additional lesion that needs to be precisely controlled; (2) it might enhance the probability of graft rejection due to a breach in the blood-retina-barrier which normally protects the retina from systemic immune influences; (3) it might produce a pathological migration of RPE cells as seen in proliferative vitreoretinopathy (for a review see Layer, Rothermel, & Willbold, 2001) . Nevertheless, the validity of a precisely controlled debridement of the defective RPE is worth exploring in models with intrinsically defective RPE cells, such as the RCS rats before implantation of RPE-like cells.
Limitations of the RCS rat as a model of photoreceptor degeneration and relevant therapies
The RCS rat, being a model of secondary photoreceptor degeneration, is not consistent with most forms of RP. The majority of the genes found to cause RP are expressed in the photoreceptors (for an update see: http:// www.sph.uth.tmc.edu/Retnet/). The genetic defect in RCS rats precludes RPE cells from phagocytosing photoreceptor outer segments, which leads to the accumulation of debris in the subretinal space. These debris create a barrier to oxygen and nutrient diffusion from the RPE to photoreceptors. Subretinal injections disrupt and wash such debris. Therefore, the larger the area washed with the injection, the larger should be the area of photoreceptor rescue. In agreement with this hypothesis, quantifying the area of retina detachment funduscopically (immediately after the surgery) is a common way of assessing the success rate of the injections. Local areas of functional rescue (preservation of visual sensitivity) can be observed in RCS rats up to 6 months after sham injections (consisting of saline or culture medium without any cells; Sauvé, Girman, Wang, Keegan, & Lund, 2002) ; these rescue areas are proportional to the size of detachment assessed immediately after the injections. Similar sham effects are not observed in the P23H rat, a model with primary photoreceptor degeneration (Y. Sauvé, unpublished observations).
Using photoreceptor precursors to repair the degenerating neural retina
Repairing the neural retina is a much more complex task than that of replacing the RPE. Retina repair implies, in cases of advanced stage of degeneration, the repopulation of an atrophied and severely remodeled retina (reviewed in Jones & Marc, 2005) by specific cell types having a precise anatomical arrangement, complex synaptic patterns and highly specialized individual functions (for a review of retina circuitry, go to: http://webvision.med.utah.edu/). In essence, the task involves using donor cells to reconstruct a complex neural network in an environment in which an unpredictable number of neurons of equally unpredictable subtypes have died and the persisting circuit has changed radically.
At the early stages of the degenerative process, replacing defective photoreceptors is likely sufficient to maintain normal retinal function providing that the donor cells can establish functional synapses on appropriate second order neurons, and that these second order neurons have not yet undergone synaptic remodeling other than with the lost photoreceptors. The functional changes ensuing from the progressive loss of photoreceptors represent substantial hurdles that will be addressed below.
What is the appropriate cell source?
As is the case with RPE replacement, a critical aspect in the present approach rests on obtaining reliable and ethically acceptable sources of photoreceptor cells. Various sources have been studied in this respect: dissociated adult photoreceptors (Gouras et al., 1991a) , micro-aggregates of developing photoreceptors (Gouras, Du, Kjeldbye, Yamamoto, & Zack, 1994; Gouras & Tanabe, 2003) , pieces of whole retinal tissue (Sharma, Bergstrom, Zucker, Adolph, & Ehinger, 2000) , photoreceptor sheets (Berger, Tezel, Del Priore, & Kaplan, 2003) and more recently, stem or progenitor cells of various origin (Canola et al., 2007; Guo, Saloupis, Shaw, & Rickman, 2003; MacLaren et al., 2006; Meyer, Katz, Maruniak, & Kirk, 2006; Nishida et al., 2000; Pressmar, Ader, Richard, Schachner, & Bartsch, 2001; Sakaguchi, Van Hoffelen, & Young, 2003; Young, Ray, Whiteley, Klassen, & Gage, 2000) . The major findings, regardless of the cell source, are that the donor cells (once transplanted into the host subretinal space) lack at least one of the essential characteristics of differentiated photoreceptors: formation of inner and outer segments, orderly array in the outer nuclear layer, adequate synaptic contacts with inner retinal neurons, or expression of specific adult photoreceptor markers.
Recent findings (MacLaren et al., 2006) showed that subretinal injection of dissociated retinal allogeneic donor cells harvested between embryonic day 16.5 (E16.5) and post-natal day 11 (P11) can achieve several requirements to replace photoreceptors: (1) successful integration in the ONL of both normal and degenerating adult mouse retinas, (2) correct orientation, (3) adequate morphology, (4) synapse formation and (5) expression of key factors involved in the phototransduction process. The success rate was optimal for cells harvested at ages P3-P7. Within this narrow developmental time window, these cells are postmitotic immature precursors engaged in a rod fate as indicated by the expression of the Nrl (neural retina leucine zipper) transcription factor. In contrast, once subretinally injected, Nrl-negative, still proliferating embryonic progenitors as well as adult Nrl-positive cells remain within the subretinal space. Moreover, though representing at best 0.1% of the grafted cells, the newly differentiated photoreceptor-like cells are associated with some level of visual function preservation in the dystrophic host.
Technical limitations
With the ultimate goal of translating such findings into potential therapies, several crucial points must be addressed. A first limitation deals with the status of the extremely large number of cells (four to 40 times more than with RPE injections) introduced into the subretinal space of mature hosts, and which, for the most part (99.9%), do not integrate into the ONL and remain in the subretinal space. Part of these non-integrating cells originates from proliferating progenitors that have achieved maturation after transplantation. The factors affecting how this large number of donor cells distributes over post-injection time in the host subretinal space remain to be elucidated. First, in the eventuality of long term persistence of rosette-like structures or multilayered sheets in the subretinal space, then, similar side effects as mentioned above in cases of RPE transplantation experiments must be considered: retinal detachments with severe consequences on the host retina (for a review see Fisher et al., 2005) and optical aberrations due to distortions of the retina. Second, information on the topographic scattering of the donor cells with respect to the injection site is essential when considering whether multiple injections might achieve full field visual coverage. The development of successful therapies also entails the clarification of several other issues such as understanding: (1) whether some cells grafted as progenitors adopt a non-photoreceptor phenotype and invade the inner retina (Klassen et al., 2004) , and (2) how the physiological state of the host retina (degenerated and therefore remodeled in the case of reconstructive approaches) might impact on the fate of the donor cells (Klassen et al., 2004) ; as long as the primary defect itself is not corrected, the host retina is bound to undergo constant changes by virtue of the ongoing progressive degenerative and reactive events taking place.
What is the optimal developmental stage of the donor cells?
Adequate phenotype and successful integration into the ONL appears to be limited to Nrl-expressing precursors. Nrl is a specific marker for cells committed to a rod-specific phenotype. It has been proposed to be a critical developmental molecular switch that promotes the expression of rod-specific genes while inhibiting cone-specific genes (Mears et al., 2001 Oh et al., 2007 . Nrl À/À mice have a ret-ina in which photoreceptors consist essentially of cones (Daniele et al., 2005) . In contrast, ectopic expression in wildtype and Nrl À/À mutants leads to an essentially roddominated retina (Oh et al., 2007) . In the normal mouse, Nrl expression is first detected at E12.5. Cones differentiate before rods (respectively, between E10-E19 and E13-P8) depending on their center to periphery location in the retina (Carter-Dawson & LaVail, 1979) . In addition to undifferentiated progenitor and post-mitotic rods, the youngest successful grafts (E16.5-P1) used by MacLaren et al. (2006) have therefore to consist of cones having just achieved their last mitosis. The negative results obtained with E11.5 donor tissue suggest that cone integration also requires post-mitotic cells. However, following subretinal delivery of P1 donor tissue, only very few cone-like profiles were found to integrate into the host ONL. For such an approach to be employed for the replacement of the defective human photoreceptor layer (consisting of 5-6% cones throughout the retina and of 100% cones in the fovea), more information is required on how to generate cone-like cells once subretinally injected. Several questions arise: (1) could a greater number of cones be generated in the host by selecting younger donors (for instance E13-E16)? (2) is there a specific developmental window that would allow a nearly normal ratio between integrated donor cones and donor rods? and (3) is the mouse retina (2-3% cones vs. 97-98% rods) a suitable model for such studies or would diurnal species provide more relevant models?
One further important point to consider is that only the cells that have acquired a rod fate in a normal environment appear to be able to develop normal rod morphology and to integrate into the ONL of the adult host retina. Once injected into the subretinal space of the host where they achieve Nrl expression, young (E11.5) proliferating progenitors are incapable of doing so. Similar findings have been obtained with older (E17) progenitor cells that were experimentally maintained undifferentiated under specific in vitro conditions (Chacko, Rogers, Turner, & Ahmad, 2000; Yang, Seiler, Aramant, & Whittemore, 2002) , as well as with fully mature photoreceptors (Gouras et al., 1991b; MacLaren et al., 2006) . In other words, morphogenesis and ONL integration would require extrinsic influences present around birth in the developing donor retina (Klassen et al., 2004) . Preservation of some of these native interactions might explain in part why photoreceptors derived from P1-P9 retinal microaggregates develop nearly normal outer segments when grafted in the adult rodless rd mouse (Gouras & Tanabe, 2003; Gouras et al., 1994; Kwan, Wang, & Lund, 1999) while age-matched dissociated cells do not (MacLaren et al., 2006) . Whether the re-expression of such crucial developmental factors (Zacks, Han, Zeng, & Swaroop, 2006 ) might promote the differentiation of dissociated precursors into photoreceptors and their integration into the ONL of normal and degenerating retinas deserves consideration.
If indeed post-mitotic Nrl-expressing homologs are the ideal candidates for the successful replacement of degenerating rod photoreceptors, then two major hurdles must be considered. First, if we assume that a developing stage of P3-P5 in rodents corresponds approximately to the second trimester of gestation in human embryos (Nrl and rod opsin proteins are not detected until embryonic weeks 11 and 15-16, respectively; O'Brien, Schulte & Hendrickson, 2003) , then an inherent ethical concern must be addressed when considering human therapies. The very few clinical trials that have been performed with such committed embryonic cells are up to now inconclusive (Del Cerro et al., 2000) . However, this is most likely in part due to the likelihood that the patients recruited in these studies had no functional RPE to allow the photoreceptor precursors to develop normally (Gouras et al., 1994) . Second, if there is indeed such a late time window, then it further precludes the use of ES-derived cells as a source for replacing degenerating photoreceptors, except if these cells can be managed in vitro up to an advanced stage of neural retina differentiation. Allogeneic neonatal retinal stem cells derived from the radial glial population have practically no potential for replacing degenerating photoreceptors in mice (Canola et al., 2007) . Differentiated human embryonic stem cell-derived neural precursors express transcripts characteristic of mature photoreceptors (recoverin, Nrl, rhodpsin and S-cone opsin), but fail to express these very proteins (Banin et al., 2006) . Protein expression by these precursors has been observed either in vitro after treatment with TGF-b3 (Dong, Pulido, Qu, & Sugaya, 2003) or in vivo after implantation into the subretinal space of both normal neonate and adult rats. In the latter case, appropriate protein expression occurred in only very few (approximately 1.5%) of the grafted cells, and these were morphologically abnormal (Banin et al., 2006) . Basic research is therefore essential to determine how to induce human embryonic stem cell differentiation into fully competent photoreceptor precursors. A recent report indicates that under very specific culture condition, it is indeed possible to obtain Nrl-expressing cells from human embryonic stem-cell lines (Lamba, Karl, Ware, & Reh, 2006) . Whether these cells can resume the function of Nrl + mouse rod photoreceptors once transplanted into the degenerating host retina remains to be determined.
Functional assessment of cell-based therapies
The anatomical preservation of photoreceptors does not guarantee the preservation of visual function. Instances exist where retinal structure but not function is preserved using pharmacological approaches in animal models of RP where the genetic defect is in the photoreceptors (Bok et al., 2002; Green et al., 2001; Liang et al., 2001) . The preservation of visual function can be interpreted in various ways depending of what is meant by ''visual function''. If visual function implies conscious vision, then it requires the activation of several cortical areas, encoding various aspects of the visual scene. Assuming that photoreceptors retain their phototransduction capacity, there must be acti-vation of the retina circuits culminating in the encoding by specific RGCs (in terms of action potentials of various temporal frequencies) of the many modalities contained in the visual scene. These specific modalities must then be sent to specific projection centers specialized in the analysis of these specific modalities (color, motion, recognition of complex shapes, etc). Visual function can also be unconscious such as in the pupillary light reflex, nystagmus, head turning behaviors and photophobia. In the case of the pupillary light reflex, it can be elicited by intrinsically photosensitive RGCs, bypassing the need for phototransduction by photoreceptors and downstream activation of retina circuits (Fu et al., 2005) . Therefore, when assessing therapeutic outcomes of any therapies in the visual system it is essential to clearly define which aspect of visual function is being evaluated and what relevance it has to potential therapeutic benefits.
For example, let us consider how to demonstrate improved visual function in rho À/À mice with subretinally injected progenitor cells (MacLaren et al., 2006) . Two tests were used in this seminal study: pupillary light reflex and field potentials from the RGC layer in superfused retinal whole mounts. Since rho À/À mice retain cone function, testing for potential restoration of rod function requires proving that visually elicited responses can be obtained with a stimulus of intensity below cone thresholds. Such demonstration is crucial if the cells to be replaced consist of rods. Using both tests, the light levels required to elicit responses were lower in mice having received the progenitors but not sham injections. What do these results imply in term of visual function? If the term ''visual function'' is associated with the occurrence of pupillary light reflex, it must be clear that this visual function represents an unconscious event. Furthermore, the possibility that photoreceptors are not required for eliciting this reflex cannot be excluded (Fu et al., 2005) . In the case of field potentials recorded from the RGC layer in superfused retinas, such activity does not confirm the activation of CNS visual centers. In conclusion, a relative increase in the sensitivity of the pupillary light reflex as well as visually elicited field potential responses from isolated retinas do indicate a better sensitivity to ambient light levels; however, interpretation of these results as ''improved visual function'' can be misleading.
Use of the electroretinogram can provide useful information with regard to light-driven photoreceptor activity (leading edge of the a-wave) and post-synaptic activation of the retina circuitry (b-wave and oscillatory potentials). However, the electroretinogram requires the summation of activity from the whole retina and can be flat when only small areas of the retina process visual information. One mean of detecting activity from these small areas is to electrophysiologically record multi-unit activity from discrete areas of the superior colliculus where over 95% of the RGC axons project contralaterally and do so in a retinotopic fashion. In this manner, a sensitivity map of the retina can be derived (Sauvé et al., 2002 ). This approach is particularly pertinent to cell-based therapies where only confined areas of the retina might be rescued. However, the ultimate proof of activation of CNS centers mediating conscious vision must come from either recording electrophysiological activity from visual cortical areas (Girman et al., 2003) or doing cortically mediated behavioral tests such as the visual ''y'' water maze described by the group of G. Prusky (McGill et al., 2004) .
Conclusion
Several issues are unresolved with regard to the clinical translation of cell-based therapies for retina repair. There is no technology yet to initiate the differentiation of embryonic stem cells into fully competent precursors capable of replacing defective photoreceptors. Further investigations are needed to identify the factors and conditions required to induce in vitro the differentiation of embryonic stem cells into fully competent photoreceptor precursors: the harvesting of such precursors at mid-embryonic stages is ethically not acceptable. Assuming that an appropriate source of differentiated cells could be generated and furthermore could repopulate the host retina, then it is fundamental to prove that these cells will not form any retinoblastoma-like tumors over the long term (Arnhold, Klein, Semkova, Addicks, & Schraermeyer, 2004; Hara et al., 2004) and that they can retain their photoreceptor characteristics while remaining anatomically and functionally integrated in the various and continually changing environmental conditions that typify degenerating retinas. The same requirements apply to replacing cells other than photoreceptors. One exception appears to be the cases of RPEbased retina degenerations. While neither human embryonic stem cells nor human RPE-derived cells display basic RPE cell properties when grafted subretinally in the actual surgical conditions, the production of trophic factors by the donor cells could alone mediate their therapeutic benefits. There is overwhelming evidence that optimal prevention of retinal degeneration (both anatomically and functionally) can be achieved with subretinal injections of cells that are readily available, safe, ethically acceptable and derived from sources other than from embryonic stem cells such as adult RPE cells line or adult syngeneic Schwann cells.
